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Abstncr: In illis pap~r we liscuss the rationale hehind biapharmaccutir::3l 
utsowcing. :we then disc!llS he b~ne5ts, chalJCIJge.s~ ClllTl!DI tr.:nds 0 andm;ukct 
opp(){tuilities. From JanWJI)' ZJ0.5. India has agae.d to carnply with theproduct 
palt:JJl prorec:tioo in accordanr:, with t!Je obligation under liie TRIPS Agreement 
ofthe WTO. Ibis has Cfl!lltec' aew opportu:tmies as we/las chalknges for tile 
Indian biopharmaceutical col11}af1!Cs.. We analyze the valueproposition ofindia 
as a ~·mlabie destinaticm for utsou.rcing in biopiJBITIJaceutical industry in tf1is 
ni':!TV busi11e58 CJJvironment T.ds IeSCarch will htdp managers lo Uilder.stand the 
be.IJe/iJs of bioplm!711accutic31?ulsourcing along with its challezrges lUJdcr the 

cunent business scenario. Her.:e, this study is timely andrefeyant Jio.rn both an 





Jn today's global economy, outs•llfCing ha.-; become a very umnnon phenomenon 
(AJvar~ et aL, 1995; Greaver, U99; Squires, 2D04). While outsourcing has b~:en
studied in traditional manufacturitg and in!Ormation technology se:ctoi.i (Earl, 1996; 
Hir.schheim and Lacity, 1993; L;city and WiJcocks 1995, Lacity and llirscbheim
7 

!993), it js still in the nascent st~e wheo applied to lhe biopharmac-eutical industry 
(BeJl, 2003; McKelvey 2000). B• outsoorcing, management can focus their cntkal 
r~sonrces and competencies OL de\'elo_pjng new drugs through research and 

development, improving marke1 ;hare., gaining competitive advantage, genetati.ng 
more profits, and achieving lJig~er customer .satisfaction [1\-kCoy and Francois, 
2003). iv:lany large pbarmaceuical companies. have ouEourred many of their 
business processes. Factors ]ike bwer costs, improved productivity, higher quality, 
highcr cUSiomcr satisfaction, tim~ to market, and ability to tOC\lS on core areas are 

some of the benefits of outsoun:.ilg. However, there are many chaUeoges and risks 
associated with biopharmaccuticaloutsowcing. 

There ar-e three major aspects oltbe proposed raearch that are s~zed by the 
following questions. 

]. JYhat are the benefits ofoutscm:ing iii biopharmaceuticallodustry? 
2. JYOat arc the major tiJctors bat co.ntribulc to dsk in global biopharmacc:utical 
outsourr:ing? 
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'(3ulhors lisrr:d alphabehcaJ/y) 
OUTSOURCING IN B!OPll4.R,,'lJA C'El/T!C4L INDUSTRY 
Globalization and Competition 
TechnolOgical affiances, especially 1D th-e areas of wrmnuni4:atioos and 
transportation have had a profound impact on the bu;siness and geogrnp hie scope of 
organization. Additionally, the openillg up of previously cJo.sed e--eonomies and the 
emergence Of new markets such as India. China, and 1he former E~tem bloc 
countries along '.vitb a prolif~ration of multi-latera] trade agre-...rnents are p.resenfing 
tremendous opportunitie.s for firm-s in their constant quest for increasing efficiencies 
and profits. Rene:; previous limitations on the boundaries of Imns are made 
practic-ally non-existent and tasks ihat could be accomplished earlier only within the 
finn are now possible by coordinating with "'iendors or cooperating with a customer 
regardJess .of geographical distanc-es. 
Vertically integrated and internal value chains within ·atomistic organizations are 
now being replat::ed almost enlirely by mter-fum cooperation on a broad and far­
reaching scale Wlth lhe obj::ctive of achieving greater efficienci~ .and returns on 
investment. Vt'ii:hin th~ pharmaceutical industry, projects are now carried out across 
several organizations by larger teams-- of res~chers 'With vartOO. skills and 
badgrotmds from dift~ri!nt countries to solve wmplex pwblems and make rapjd 
advances in drug discovery. g-.momics, bioinformatics and pbmnaceuti.c-al 
manufacturing (Valazza, and Wada, 2001). As a resu.l~ r:;e-....- products, new 
technologies-and services are developed more-quickly and meeting i:he specific ne~ds 
of thf fmn by taking advantag~ of global coope.ratio!l in the tOrm of .!>O'ategi5: joint 
ventures, oul::;owci.ng, or some varianls of teams having complementary skills and 
lower costs (Valazza, 1998). · 
Collaboration 
For the present day pharmaceutical industJy, collaboration is an increruing.ly 
important and ..;:ssentia1 business modd Vendors work ·with clients to shar~ tbe 
d::velopmeot wo•k aud hence the assO<:iated JisJ.-to improve ne•~rly created product:s, 
custom products, technologies and services. Tb:is is particularly important for Oio­
informatico; tools veodors as it is not always possible io create ubiquiiow .software 
tools that cat-er to d.lffereot customers as there is always a need for cuslomiiation and 
tweaking during technical development to suit incif....idual requ:irements (Kim and 
Bucbanan, 2003). . 
For biotecbnology an<l pharmaceutical companies, the rnagnltude in tl:Je cost. of 
development of "iable products is extremely prohlbiti'ie to restrict _selling only to 
local ma:rk~s. Hence, there ts a real need for access to Di!W markets to sustain profit3 
and long tcrm grow1h. There -is a global trurrket for similar health concerns in every 
part_ of the world- such as hypertension, migraines, obesity, allergie-s, and life 
exi~ion etc., pre.si!ntiog opportunities for ·fums 'm developing countries in tei'Trui of 
partnelShips and outsourcing vendor relationslUps with North American and 
European drug firms which haw~ h'ad a head start o'o'er the former {V.-S. Departm.:nt 
of Commerce, 2003). 
Bio-Pharma<Cuti<allndustry Problems 
High CO'St drug discovery Cc-onomics is only a part of the problem faced by the 
pharrna"Ceutica1 lndLJStry which i_s al;.o characteriL:ed by escalat~d investment 
expenses for research and development, length of time for FDA appro\·al and time to 
m.at..cet and higher c:ommerciali:zarion co:;ts {Siefan., 2001). Th;!. total investmrots 
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need _to almost _dou~le to sustain p~vious double digit growth rates. Price 
~::ontammem tacll~s JmRosed by .medical inswance companies, rising coosumer 
unre.st ovei the high pnce.s, aDd mcreased comp~titive intensity baH: exacerbated 
roarkel pre~~es on plUmnaceurical .fums to decreale costs of drugs, cesearch and 
develoP_OJenl Investments, whik generating higher and higher returns On investments 
(DiMasi e:~ a!., 2003). 
Th~ ~tiooaJ nb_igger-tbe-be~er" model of pharmaceubc!il C-Ompanies with 
ma:sstvi! mve-s.tm-enis m.the mgamzation and waiting for the discovery of the next 
loi1e·~ ~g. _ccut:s .senous do~bts on the sustainability aod longevity of mch 
orgarnzahon~ ~ the present busmess conditio~ in S-pite of favorable outlook on the + 
Agrotv1h of tblS tndustry (Polastro and Tu.Jcinsky, 2000). The most difficult cha1leno-e UJ 
is- the lmp~~g expiry ~_>f p~tent rights to several of the blockbuster drugs in the A' 
market, potentJ.ally resultm? lD seve-ro: loss of rev.:mue tOr the original innovators. I "' 
furthem10re, many compames seem to be operating on borrowed time in anticipation A 
of the next blockbuster drug. According to industry sources, drugs accounting for "' w "' 
almost ~5o/o ~f the total sale.s translaTing to near!}' 80 billion dollars are set to Io.se A 
patent nghts. ~ ~e lXOO. 5 years and are open for competition fr()m gerieric drugs. "' 
UJ "' The pres.sure IS higher than e\ier for the need to shorten drug development time and 
;peed-to-market (Robbins, 2000). 
2. Benefits of Out:wmcing in Biopharmaceutical Industry 
The: pace:. of new techniques in drug di.scovery are invented faster thau can be 
mastered_ by . ~y individual company, and planning ~arefully the sc~ of 
?ulSourcwg W1~ _the r:search and d~velop~ent agenda can have excellent payoffil 
m t-eiTUS of utilizing locally non-eXl.stent lttbnology, cost and overall product 
de:velopment time. 
\~~ now examin<i: in ~et~l ihe true benefits of outsourcing as a strategic bus.iness 
d<i:ClSIOO to acqwre spec1alized and compk-mentuy assets/technologies not existent 
within the firm. 
Rednce R&D Costs and Improved Margins 
Major pbarmaceutical industries spend up to 20% of the total sales in R&D and 
have traditionally sought t~ reduce spending by engaging in .selective outsomcing of 
~~ental researci:J acti"¥Ibes to universities, govanment Jaboratories and ce.search 
ms~1\u~es. H~dreds of in~epend~t n~ gene.mtion biolechnology companies bave 
be..n mno~almg new tecfl.DologJes a1med :u drug discovery and development, 
outnumbenn.g tire total number of pbam:mceuticaJ products available in the market 
(Douglas, 2002). 
Biote~h ,~. have strat~gically reoriente-d themselves ~s "drug discovery tools 
c~mpames au:ru-ng to ?roVlde- research services to drug discovery companies, and 
r..se~nch spending by biotech firms alone was e.s.timated to b~ about $11 billion in a 
report prepared by Emst t! Young for the Biotechnology Industry Organization 
{Ernst & Young. ~000) It ts practically impo.s.!>ible for any single medium and small 
SIZed ph~ceutacal company to beat t:l:Je pace of innovation at the applied researd. 
leYe) and stay ahead of tile ex1~rnal firms creating mnovation in their respective core 
competencie.s. "' ~-A 
O{fTSOURC!NGll'trBIOPH.4R:t;!ACflJ7lCAL /lVD(.JSTR Y 
When the Swedish biotech fum KabiGen decided to make 1ls foray into genet](; 
engineering for lhe manu.factur.:: of pbarmaceut.J.cal products, they dld not have any 
resident expertise but were keen oot to miss the corumCI'Clal potential -of this new 
teclmology. KabiGen decided tt:> jump S1art into the new te-chnical traj-ectory by I 
t;Ontracting R&D work to Geoentech who bad deveJo)led research competences and 
different genetic eogineering technique.5. Kabige.n essentially funded Gene.ntecll to 
create new scientific techniques: and ~orbed tbe knowledge in-bous.e. Without 
such innovative contracti.n~ it would not have been possible for Kabigen to move 
quickly i.nto the commercial trajectory of using genetic ~gineering into its 
pbarmacoutica! production system (]\.lcKolvey, 2000). 
Teece's (1986) ta.\e OD profiling from R&D is by allocating R&D resources 
towards. new products that can be potentially commarcialized quickly using the 
existing capabilities within lbe fum- the assets and revenues of the finn IJ.lUSt 
ccnclition and guide the R&D investmeni decisions. 
Establishing A.Uiances and Ou.tscrurcing Contract Research 
E:~panding into international markets is an Jmportact strategy fm American 
companies to optimize the potential for sustained revenue growth. Common 
heallhca:re needs of customers. across !.be world dlrect1y translate into opportunity. 
Accuriling lQ the 2001 BioteclmoJQgy Indrntry survey report by the U.S. Depanment 
of Commerce, international markets accotJ.nted for approximately 16o/, of the tota_J 
sale.s (which i.s: about S8 billion in r::venues) ofbiotedmology firms. i:n2001. 
It is a clear strategy to reducing th~ risk in th: compJex and Uf!Jlredictahle process 
of drug development. It helps to target resmn:ces in creating innovation in new 
directions. The freely available human g~nome sequence data from the public 
project has triggered an expkts.ion tn the pace of resean:b worldwide and an 
.integrated structure with scope for outsoun:l.og portions of R&D is the model of 
indlffil"Y wide re-structwing. 
Access to New lnternatioual Markets 
To-ere are leveraJ strategies employed by multinational pbarmacwtic-als to increase 
thcir geogra-phical r::acb and international participation such as direct export, 
licensing, international strategic alliances tbrougb partner.iliips and outsourcing 
agreements and Foreign Dire-ct lnv<:Stment (FDJ). Din:ct export and licensi.og 
strategies are low risk ventmes but coutrol over !he product is mi.nirual and 
'(;<lmpetitors can quic.kly duplicate and erode market s.b.are. 
Strategic alliances are punued wben firms have complementary capabilitie' that 
w.hen combined can resuJI in competitive advantages, locaJ fum's knowledge of 
government regulations and market conditions can be exploited to quickly. acc-ess 
Jocal cllanoels of distribution and the relationship can -be e-xtended to .manufacb:Di:ng 
311d sourcing of raw materials when tl:J.e market conditions for the product or services' 
are more clear. 
For mediwn and smali iized fums strategic outsourcing aJiiance.s paves the way to 
.'!baring complementary techno1ogies in discovery processes, re.searcb, and 
manufacturing capabilities. Conditions: for optimal scale of economies are created 
by bringing resources together. 
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Cost considerations are very important to be able to compet~ in international 
markets e;SpeclaUy in ..&\sian markets where the earning potential of COilSll"IDers is 
enormously ]ow in compari!'.o.n wi.tb tbe. American or European coun!erparts, it 
mak~ business sens~ to lotally manufacture and leverage corporate high quality 
wntrol, brand equity and best practices lo capture market sbare. 
Tapping Global Skills 
Wben the task of sequencing the human g.::nome was launched thirteen ye-ar~ ago, 
th~ compl~x.ity of this project originally estimated to take approximat-ely- 30 years. 
However global collaboration and utilization of global ccmpetencies among 16 + 
Ar:seartb laboratoriej worldwide made it possible to compl~te this colo~al task 
within 13 years since il starled. "' A' 
.Most ni!w innovations in any industry are dependent on computing poweJ and "' ' software. No single R&D ~ntity in the wor1d caD predict all the possible A "-' cccombi.natiOil.S of applying software and computing powe1 to innovate all possible w 
potential new produ~ and process-es. .p. "-' 
.t;,. fum can strive to gain competitive advantage over its couoterparo; by "' 
di3cOV"ering .sourc~s of )ower cost or di:fferentiatio-D in any of its activities (Cullen, "' 
2003) from any part of the wDtld .>ucb as; 
New ideas and teclutologies 
Source of raw materials 
Effi~;:ient manofacturing capabilities 
Lower labor cost in other cotinlries N 
Lower R&D cost in other countries ~ 
RefOCU"'illg on Core Co-mpetencies 
Di\:ersified corporations aim to create and increa:;e shareholder value by 
strategically orienting themselves. as ertbc:r focused on creating .new and innovative 
products or as a service-..s company adept at efficient business processes focusing on 
cost effective manufacturing solutions and logistics. ]be pharmaceutical .industry ls 
re.:~earch and development intensive and hence pro<h.K! dnven. 
rne U.S. Patent law~ aUows patenting of ne.wJy discovered drugs but noi the 
extraction process of the drug, wi1.hout offering protection from imitation by a 
Oi.ffer~nce in jUst a single molecul~. Product differentiation and advertjsing placed 
high importance on the adoption and market demand. Heo~;;e phar:macet~tical 
companies invested in tbeir O\'tll manufacturing capabilities, sales and distribution 
charmels as none of these segments were easily available i.D the e<tlemal market at 
competitiv~ prices. 
The critical task for the .ma1l3gerneot in the mosi. simplified terms is I() creak new 

drugs ilial almost llav::. no side effects, and invent.Wg n~' drugs that customers need, 

but none ex.is~ .in tbe market. This ofcourse js a highly difficult and decepti"Ve task. 

The ciJa:nged market conditions have given rise to a wide range of diversified 

companies specializing in different seg.mwts of the drug discovery process creating a 
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R.efocu.:.ing on core competencies allow to comp~te rigoroU;:)ty, for some 
companies it might be mar~ suitable to oulSource th~ir macketing, sales: and 
distribution functions, while other companies find it more su.i.table to license drug 
compounds from other companies and capitalize on their own brand equity, 
established marketing and sales networks and geographical reach. For example-, 
Novartis Pharma, a Swiss pbannaceuiical major signed a license •.vith a lesser kno\'..n 
company Sigma Tau to d;.welop, manufactme and commercialize the drug compound 
Gi.mate(;an having therapeutic vatues for the treabnent of cancer (Noyartis Media 
Release) 
Time to Market 
Time to market is a very critical factor and is often the biggest deciding factor 
between succ~s and failure of the product as first-to-market vrins the allegiance of 1 
the rnark.et. For example Pfl'Zer' s Viagra generaled sales of 1.9 billion dollars in f 
2003 alone and still owns a major -share of the mruket in spjte of at least two new a-
entrants Cial.is and Levitra 1o cbaJlenge its n:tarket dominance. :~ 
The early phase of the res-earch can be isoJau:d into its constituent steps of l£ 
cbemical, biological i<:reening .services involving isolation of compound using latest ;. 
computational power and automaied high speed screening by opportunistiWly -~ 
ou~ourcing relevant areas can resuJt in shorter development time. 
Many of the phases that are typically <:xec.ut.ed in a serial fashion can be done in 
parallel, by outsot.D"Cin.g operations management to companles \hat excel in provicling~ 
efficieDt drug d~velopment timelines by conducting as many steps in parallel. Ta~ 
ability of the external cOIIJpcmy to delect lox.!city of specifac J;:ompounds, and perfonn 
target validation efficiently c-an save time and speed up the proce.ss. Outsourcing 
makes it possible for the .sporuonng company •.o c<m.et.l.Irently run multipl-e promising 
projects due to the additiouaJ n:.soun:;es pooled in from the vendor. 
In tenns of aiming to reduce the lime span of Lhe product development life cycle. 
much potential results from mw technological i.IIll.ovation.s. that are made available 
al.mo.:;t continually by vendor biotech companies focused on innovating tools for 
drug discovery and ~.stablishing outsourclng alliances with such ruganizations can 
lead to successfuJ compoletioo ofproject within or exceeding time.scales. 
3. Risk Factors 
ln l.bis. sec;:tion, we di:scu..<:.s voarious .risk factors that are specific to blopbarmaceuticaJ 
oul:iourcing. 
Protecting IP through Parents 
In the baotech and pharmaceutical industry~ finns hope to earn mo11ey through new 
innovations and creating IICW technology ratber than end product differentiation 
unJike in other industrie.-;. such as carumner goods or automobiles where innovations 
are more easily duplicated and they rely on produ<:t value competiticm_ Pat~nts are 
higbJy effective and remain the singlo: most effective strategy of bJolech companies 
to protect their intell~ctual property rigbh. 
The U.S. Patent system is a "giv~ and take', bargain agreement between the 
inventor and the govemmwt. The inventor bas to fully di5cklse to th~ public <•the 
invention'' in exchange for a government pmrected. exdwiv~ right to e:vo:plo1t tbe 
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invention in the U.S. for a limiled h.me period (Biaug, et al., 20()3). Patenting allows 
tile inventoG to fully exploit the commer-cial potenhab of tb.eir illvomlions wilhoot 
risking theft ofth:::ir R&D effort by other competing firms. 
Give:o tbe higher levels of investment and risk needed tOr the development of 
commercially viable inventions and processes related to drug discovery and 
development, the time {)etiod of patent protection for patents inowohing drugs is 
much higfl.u (20 years) and a r-equest for a fiutber extension of patent nghls for a tew 
more yeau can be fil-ed when nearing the end ofpatent life. 
+FDA Regulations 
Biotech and pharnla.ceutic;:al companie.i choosing to ta..'<e advantage of contrac.ting 
fums for outsourcing any activity in the drug development need to be cautiow; ln. 
ensuring the compliance ofccgulato:ry requirements of FDA. Vendor fums provide a 
mean5. af acce5s to resources and ex.pertlse without high capital investment (;Osts tn 
equipment. It doe-> not necessarily mean that tbe FDA regulatory requirements are 
adhered to unJess specified in the contracts and the contract firm bas iTJ.herent 
capabiliti~ and methodologies in place foe such compliance r~ir::-ments. 
If the contract fum violates FDA regulations, there are potential implications of 
.iignifi.cant liability to the client and there ls a risk of attracting legal sanctions and 
invoh·e-. .i product seizure, c.ourt injunction and penaitie:'l. To mirigate such risks, the 
client company .s.bouJd take precautionary measures of i..nterviev.-ing references. 
review the ,,.endor's regulatory files and establiliibment inspection cepo:its at the roA 
and consider track record-s of earlier dealings with the FDA (Kim and Buchanan, 
2003). 
Mainlllining Quali'Y 
A quality agreement between the contractor and tbe c!ienl, clarifying in significant 
detail tb<: quality and regulaoory compliance obligaiiC'IlS is an important instrument in 
maintaining quality concerns during outsourcing. The agre::ment must specify the 
documents that Me expected from the cootractor, address tbe conmum.icatwn of 
deviations and re~oasibilities of <:orrective actions, roles and responsibilities of 
audits and inspectio-ns~ and communicatioo of complaints and recalls of raw 
mate~~ls etc., "GuidaDce for Industry- Ccoperai.ive Manufacturing Arrangements 
for LJ.cerued Biologlcs'" document published by the FDA pro-..'ideJ. some excellent 
examples of Quality Agreements in the biotech indwtTy (FD:\, 1999). 
Pitfalls to Avoid 
"On>! size fits aU", every oufsomcing contract is unique and differ-ent. 
Outsou.rc:fng is not an opportunity to offload intanal probl~ms. not .knowing 
what to expect will only 1::-ad to uncertainty in evaluating the level of 
5uccess of the result 
4. Tapping Offshore Resources-llldia 
Western multinational co.mpan]es are attracted to India todav more than <:'rei be.fo.re 
as it offers a way to reduc;:: costs in e-..-ery industry, from s~ftwa:re developmeot to 
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returns preparation. The s.::cood most importmt reason most large campani~ 
pwposc: to expand abroad is iD search of spc:cia.lized capabiliti~ that are not 
available locally. 
A study by a group of researcher> (Chung et aL, 2002) lind "knowledge seeking'' 
is highly prevalent among companies associated in Research & Developmeni­
intensive industries such as pharmaceuticals~ seo:riconductois and electronics. In fact. 
iheir research shows that drog makeiS are twice as likely to seekkoo w/C!kc: abroad 
as companic5 in any other industry. c 
Bio-pharmaceutical industty in India- a Background 
India is one of the largest aDd cheapest producers of therapeutic drugs in the 
world; lt stands foremost am-ong the third world and bas excellent technology, R&D 
and production facilities; a <wide range of quality :roOOicines are made locally fOI" 
most medical conditions ranging from common fe,.·er lo soeciaJized annbiotics. and 
vaccines (Maria, Ruet and Zerab, 2003). • 
·Traditionally the industry has been only excelling in Teverse e:ngineM.og and 
tweaking ofdrugs fucused to sell ill the dome&i.c market Ho\\..ever~ with the product 
patent rights regime going inlo effecl from 2005, the major players in this industry 
Table 1: Key Bio .Plzam-JaremicaJ Compaoies roci.Jsing oa Rr:s..-.:m:b & Dffvelopmeotin India 
9 
Dnportance of original R&D 
are forcibly undergoing a strategic shill. in thelr busiDess. models. 'They at¢ mo·...-ing 
from being copycat generic drug manut""actnrer.l to innovative drug firms in order to 
·move higher in tbe value chain of th¢ industry and have woken up to realizing tbe 
wo.rk that could lead to filing for internationally 
patentable New Chemical Entities (NCE) t~ reta~ l::Ompetitiveness. _ . 
Buoyed with the SllCl::ess of the IT s.ervtc_es mdustzy. the government IS achvely 
__.........en2aging to promote the bio-plwmaceutical Uldustry by focusing efforts on R&D for 
cr;ating new molecules, microbial enzymes. gene expression teclmologies and a 
nm.ge of genoalics and proteomlcs related activities targeting export markets in drug 
discovery and development. 
India bas acce.ss to vast resowces of well educated and talented workforce and a + 
slew of resean;h centers and world class laboratory facilities. There are a cumber of "" 'f' 
research activities in progress: Biocon. Dr. Reddy's laboratories, and Ranbaxy are ... 
some of the leading companies that have filed for international patents as shown in "" I 
Table 1. Indian companies have begun to successfully create strategic allianc-es "\Vith "" 
CD "' global heavy-weight pbarm.aceuticaJ companies in the areas of drug discovery, w 
development and manufacture. In addition to high growth rates (Table 2), as shown "" "' in Figure 1 India is a] so quickly emerging as a preierred destination fm contracting "' "' ~arch in biotech products such as recombinant techniques, enzymes aimed at drug 
dlscov«y, diagnostics and contract manufacturing (Cborghade eta!., 2001). 
The presence of a large pool of research oom.munity that is fluent in English 
languag-e (biggesl outside of the U.S), biodiversity (presence of a l:uge Dl.IIIIber of 
div::.rse ethnic population)~ a growing technologicaUy sophisticated pharmac;euti.cal 
industry (the industry is poised to grow at a rnte of 25-30 percent) and India's 
signing ofTRIPS \\'ith a pledge to fulfill the agreements. has triggered a large number 
of western alliam;es with local Indian pbcmmccutical and biotechnology firms and 
fhis trend is expected to continue. Some of the high profile partnerships arc described 
in Tab1e 3. 
Smaller and intermediate size comJlanies tl)ing to make a foray into luWa must 
explore tbe pos.Ybilitics of forming a strategic and gainful partnershjp based on 
complementary capabilities; success is hard to C"Olll-e by \.\oitbout such alliances as 
Indian .firms are highly competitiow·e. pric-e and sen-ice-capability wise. 
India: Pharmaceutical market 
B Fcrmulalial drugs 
BBulk drugs 
ae-x~crts 
Figure I: .P.ha.ntuceuticaliWarker Re~rn11e .BTU1iarp [Sowu ofdata: OPPI] 
- - - -
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Thcre is an enormou-s scope for outsourcing and cooperative joint verrtur:s in the 

areas of contract re.SI!arch for drug discovery, design, synthe3is aod manufacture (of 

pre--designed) cornbi-chem libraries, fonnulalion development, chemistry and 

biology services~ clinicaJ trials and tcx;hnical documentation writing according to 

regulatory gwdelines, contract manufacturing of drugs coming off pateDt (sunset 

drug compounds) etc,. 

Many of the Western biotech and pbarrnaceulicaJ majors have large librari~s of 

tbeoapeutic compounds and molec.ul~ but n~ver prioritized for commercial 

doiWelopment because of its lower -market potentials. Strategic partnerships ~'ith 

Indian companies can bring low cost clinical trials and manufacturing capabilities 

yielding n~ revenues with minimal inv~:stment and risk. 

Clinical Trials 
Conducting clinical trials forms a significant portion of the drug development 

costs and is time intensive. A heterogeneous pool of genes and the availability of a 

large nwnber of patieJJts have attracted a number of companies such as Pfizer and 

G!axoSmithk.line to conduct clinical trials in India. According to estimate--S by Kotal 

securities (2003) it is 40-50% <:heaper to conduct clinical triaJs in India comparOO to 

d~velope:d markets due to the availabili-ty of a large number of physicians, good 

clinical practices training and the sp-eed of patieni recruiiments. 

However, while most moltinatioDal compani~ conducti.:ng 'lllinic-al trials in India, 

do .'io througil their fully owned subsidiaries, the d;;sign and thi! protocols of the 

clinical trials is stiU not done in [ndia but in their other facilities. Only tasks '\\itb 

cleo.arly defined ·inputs and outcomes are executed m Incha. Pfizer, Eli-Lily, Astra 

Ze[]eca are k:w of tbe international companies that are successfully condocli.ng 

d.ini;cal trials in India. Th!- sponsor!ng client company has to take the initiative io 

design the protocols. monitcring criteria, and pre define data managem~t guidelines. 

Th~re are very few independent Contract Research Organizations that are already 
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capable oi doing tbe.se tasks from start to finish without hand.haldirtg. If a client is 
seriously pursuing cli!J.lcal practices in India. the following are the leadil1g 
companies specializing in this area and c_an be explored for potential joint venture 
partners or outsourcing: 
Clinigene International Pvt. Ltd. 
Lorus labs Pvt. Ltd. 
Siro Clinplmm 
Advantages and disadvantages ofdoing clinical trials in India are listed in Table 4. 
Contract Research Services 
The Department of Biotechnology (DBT) in India has been iretrumenlal in 
creating basic infrastructu:ral facilities to accekrate R&D in the areas of molecular 
blology and modern bioteclmology. Numerous national laboratories and -univcrsi[y 
grants has resulted in a large number of fundamental resean:h projects in the areas of 
fmlctional genomics, microbial genomics, buman genome diversity, 
pbarmacogenomics, prot-eomics., &elll cell\, bio-computing etc., and has resulted in a 
large pool of lalented mearcl> (Patel, 1997; R•dolpb and Mclntire, 19%). 
The prognuns Uritiated by the DBT have: developed scr.:ening: progmrns for a wide 
range of prevalent genetic diseases such as s.ick1e cell anemia. tbalas:5emia etc., and 
also resulted in sevetal indigenous diagnostic technologies using genome 
intbrmation for diseases such as AIDS and vacciDes for rabies and malaria Reliance 
Li.fe Sciences and the Nati®aJ Center far Biologic.aJ Scien<;es are among the 8 ~ 
institutions in 5 coo.ntries that have been id~tified b)i National Institute of Health 
(Nlli) in US as sources of embryonic stem ceUs eligible for U.S government federal 
limding. 
International phatmaceutical oompanies .ho~r have bc-.cn vwy apprehensive of 
making aoy sigui:ficant R&D investments in Indla, mainly bttause of earJier bad 
experiences with weak intellectUal property protection laws. There is a change in 
attitude and mind set since tbe signing of WTO and it remains to he s.e.en OOw the 
industry shapes •P pMI January 2005. 
Presently, only few private Indian biolech C<lmpan.ies such as Syngene, Aurigene, 
Shaot.ha BioteclDlics etc., bave untkrtaken contract research service..s for European 
and American cJients and n:ruch of the R&D tapabllities lie in the goVernment owned 
pnblic laboratories anci there is scope for many improvements in the areils of 
regulatory procedwes, woTld class tr.UniDg on GCP (Gond Clinical Procedures) and 
io~!J«tual property protection before the R&D apabilities of India can be fuUy 
exploited. 
Coottact Manufucturing Services 
AccOTding to OPPI, there an: about 60 (FDA Approved) drug manufacturing 
plants in lndia which is tan..'::ed second only to the U.S and corr~-poudingly the wortd 
no. 2 in Drug Master Filings (DMF), which is IIIJIIInfacturing nf bulk drug! for 
supptyiog to otbcr large generic drug makers arid for self cOOSUIDption. Kottk 
Sewriri.e.s reports, lndial accounted for 34% of the global Dh-:IF filing.!: in 2003 
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intemati~nally competitive prices and there is a large pool of scizmtific talent and 
engineerutg base. 
Bioinf0l'Ill2tics and IT Services 




and d~velopment, as the services and staiJdards are beg:inn.Wa to h 
marured well defined proces.ses .in place, bio-pbannaceLJtical tfuns ar: 
beginning to ireal 'bio-infonnatics• as a more standardized componenr not central to 
their cOJ"C com~et~.cy ~~g djscovery) and are outsourcing bio.mforroatics projects 
to vendors spec1aliziog m ti. 
While the global bioinfo1111atics ma:rkct is estimated to be $0.8 to Sl 4.6 billion 
(U.S. Department of Commerce), the Indian market is estimated to be a miniscul ... 
$2.2 million (Confederation of Indian lndu.stries). The Indian bioinformatics marke~ 
is estimated Ia grow to approximately $15-20 million by 2006 (Prabhu and 
B~_gwadia: 2003), an~ IDC lndia predicts a more exponential gro..-'lth to nearjy $130 
million ~amly from distri~ted co~puting, storage and data handling~ data mining, 
geno-typmg, DNA-Seqllencmg appllcabuns. and software ~rvic::.s. 
1ndia's Advantages in Bioinfonnatics 
The oombers indicate tbat the bioinforma.tics indtJS.try in India is cleaoly stiU in its 
infuncy state but th~ business conditio11s offer a tremendous opportunity in view of 
tho: presence of the strong Informatio!l Technology knowledge and skills and tf:Je 
local presence ~fa. large ~umber of biot;:~ology and pharma<:eutical comp-ames 
lhat are hungry 10r mnovabve ]ow co.st bto-infurmatics soiLJtions targetino a ranoe 0 of
activJties from drug discovery to data management. co 
Tb.e govi!mmea:t bas be.:-lJ ~areful not to miss the bJo-infonnatics opportunity and 
was ~talm establishing the _Deparn:nent of Bioteclmology India (DBT) way 
back m 1986 lo oversee tbe establrshment of ~cessa:ry i.nftastructure by creating 
Btotechnology Information System (BTIS) network 1hat connects 57 researcb centers 
ill.""'tU.SS tile country 1Q provide state of the art tools, edocation, and information in 
bioizl!ormatics. lbere are many centers of ex~:-ellence tbat have developed expertise 
and mte~ectual ~perties ln COJIJputet simulation, molecular modeling and bio 
~omputatJ~ appll~tJOn_s: Many &peeialized educational programs have bem 
mtmdu~ed In tbe lUllVersttle.i by DBT to m~,;:t the cbalJe:nge of skilled technical 
professmnaJs. 
lndia's Challenges in Bioinfonnatics 


Tile. key to realizing tbe bio-informa.tics revolution in lndia is the rec.J:mK:al 
exp~rtJ.se.and s~ oi manpower, vertical knowledge in IT and ..,uperfk.iai knowledge 
of~fe sCJences JS not enough. Substantial levels ofdevdopment siriUs are aecessaiJ 
~ mtegrate disparate fieids of life sciences, mathematical kno\v-ledge with the late:st 
m ~formation ~e~hn~logy. "The management challenges of sucb compllcated 
proJects are not triVIal e:Jther. Thete is a shortage of this highly sp:cializOO wotkforce 
to_ be able to ~up~cate- the low cost suc.~s sto~es in standalone IT aPJ)licatiOilS. 
Tbe entry oarners to small compamcs are high and the venture capitals aod othe.r 
SOUTC"'~ of funding are difficult to attain since prodnct development time and Rerum­














within the US, mostly by small and m-edium size businesses as larg;;: companies tend .i 
to have the capability within the firm. Convincing companies [O ou1source projects 
to lndia can prove a slgnificant mad:eting challenge. :~ 
•
LateUectual Property (IP) Development and Proteclioo 'f 
The Indian Patent Act was passed in 1970 to protect imellectual property~ tbe Jaws Ji 
were formed to limit the influecce of powerful multinational drug firms from ·:=4 
monopoly, and there were many elements of safeguards introdll.Coi:d to ensure easier ~ 
access to drugs by common people. Product patents were no1 protected and on1y the 
process by which the product was manufactwed is patentable and the duration of a 
such patent enforcement e~isted only for 7 years instead of f4 years elsewhere. ·~ 
lt allowed India to produce generic drug.s at a fra(;tion of the cost ·compared to i 
Europe and America, leading to a rapid increase in tbe domestic production of 
generic drugs and bulk fo.rmulations, many of which we:ra reverse engineered and '"$ 
molecular lev.al tweaked copies of block buster drugs. 1be domeS1ic phannaceutic.al 
industry bas grown itsmarl:etshare from 25% in 1970 to almost 70% presently. 
The loopholes i.n the patent laws largely prev~nted global pharmaceuticals to view 
Indian market with smpect and ha>.-e prevented any slgnificmtly Jarge deals in the 
subcontinent. India's entry into tb.;: \VTO fold in 1995 and its agreeing to ratif; all 
the obligations of patent laws from 2005 bas forced a paradigm shift in the 
p~ctives of lhe globaJ biotecb and pharmaceutical multinationals. 
See Tables 5 & 6 for rel~ant Indian laws and the implications ~f lndia'.s 
membership in the \VfO. 
Table 6: A,;; a WTO sigDJliofy, lhe obligatioJJS to be MtiJJ~byindia 
.DllAR AND llA.IA.liJ 
Regulatory AffiUrs 
lndlan co~im~s a~g at the global market use the USFDA guidelines for dm~
approvals whicb JS t"Qnstdered the most rigorous approval proces-s. There is an 
absolute lack of o_ne single ag_ency ~ takes the responsibility to rosure the safety, 
efficacy~ and q~.hty of drugs m India. There are multiple agencies that are serio~Jy 
undemaffed which ove:rsee the drng approval process and take an indeterminate time 
to evahlate n~w drug applications (NDA). Th: Prime Minister's commission on the 
sluggish growth of the biotech industiy in spite of $500 million O")lenditure by the 
gov.:nunent 1deotifi~d complex drug approval system as the tna.iiJ. constraint {?vl~ 
Ruet, and Zerab, 2003). 
There hav-e been some significant efforts to reform the Jegulato-ry affairs related to 
drug development and clinical trials in lndia on the lines of the FDA; the Indian 
govemm~t has made it compuls.ory to follow the technit;:al requirements mandated 
by JCH ~ternational . Conference of Harmonization) for registering all 
ph~c<:utJcal products tntended for lnnmm use. Compuls.ory following of Good 
Clinical Prae1ice guidelitles for clinical r~e.arcbes designed to be condw:;ted in India 
bas bee.n mandated 
Until re<:ently, the Indian goyernment regulations for drugs required clinical trials 
for new drug:s. not d.Ecover.ed in India mrn;t be one phase behind the rest of (he wor]d 
and phase ll and phase ill trials for ne•N drugs were not a11owed simultaneously. 
There have beet~ recent amendments in the Indian drugs and cosmetics act (schedule 
Y) to de_,cribe newer guidelilles si.m.ilar to the FDA's for clinical rriaJs. and allows 
simultaneous Phase D and ID triaJs. However the recommendation to allow Phase I 
triaJs ofnew foreign drugs in India co.ncummtly with those that are cooducted abroad 
is yet to be ratified 
Key Reforms 
In response to t.be Indian biotecb and phanna<:eutic.aJ indu:stries pl~s. the 
govmnne.nt has la.ken some positlve ~asures to increase R&D activities and 
encourage foreign partic:ipmion in the industry. -n.<!re are proposals to 
Scrap the pri<:e <:ontrof lactic.s of the govemm~nt as this is a major 
discouraging factor fcr R&D investments for new drugs which warrants 
huge capital investments. Price control redm:es return on investments and 
stretches the time span dwi.ng which the ~osrn can be reocoveied However, 
the government is. wi.l.ling to reduce the number of drugs in the purview of 
price control and gr.adva.lly move away from price control o.n bulk drng.s. 
Allow conducting of Phase 1 trials in India simultaneously wru!e being 
carried elsewhere as t1lls will lead to faster access to new drugs in India and 
promote the growth of cli:nical trials -business revenue in India due to 
significant costs savings factor. 
Refor.m and stream!i.n~ the reg-ulatory ag.ancies to grant approvals in a 
timely pr::dictable marmer and encowage a single agency for approvals on 
the lines ofthe USFDA 
RefOIIil tl:Je potency of the patent protection ageucy by strengthening of the 
appropnate legal :funneworks and higher penalty for violations. Increase tbe 
size of patent specialist staa"'f which is currently grossly understaffed to 
handle quicker processing ofpatent applications. 
 
+ 
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Bioeth:ics 
In spile of the existence of some faws and legislations to protect bio-eth.ics for 
humans, India Jacks th~ frameworks, mechanisms and appropriate provisions for 
strict enforcement of the legal requil:emena. Th~re have been many instances of 
violation of 1he poverty, illiteracy and ignorance of certain .sections of people to be 
recruited as clinical tria] patients and treated as guinea pjgs without proper consent 
and information. International companies conducting clin.icaJ triaJs in India need to 
ensure the vendor company's compliance and historical credibility of confirming 1o 
intematiooal norms in order to protect itself against public bac!dash due to 
neglige-ace. 
Genuine Rlsks and Co.ncern& 
In spite of tbe enormous potential for India to grow in the area of biotechnology, 
the immediate benefits ior ntultinational firms may not be high. There are many 
cha.lk.nges in securing good infrastrncture sncb as faster transportation,. power and 
bandwidth. The JT i:ndu1tiy bas thrived and prevailed in spite of the enormous 
shortcomings b)' operating as small island:> of prospenty by building lheir own 
captive muastrocture -SUCI:J as local power generation and facilities. However, the 
investments needed for similar operations of bio-phannaceutical companies are 
much bigber and the r-etmns take much longer. 
There is widespread CQffilptk:m while dealing with government organizations for 
logi5.tics and establishment. H is. very important for srna11er and medium sized firms 
establis.hing offices in India to use the sorvices of <:ompanies that specialize in 
providing legalities, logistics and tax are-as. Choice of the right vendor wbo has 
historic--al credibility and can help make things happen. a part:na ·with a 
compr~ens.ive sel of capabiliti~ 1hat can be Ctlslomized to the client's spec.ific 
needs \\-ill decide the success or failure of off-shoring endeavors . .Many participants 
of our survey baw·e expressed discontentment on the bureaucratic problems and have 
bad e;,.itt:d :from the Indian market, in spite of having the advanlage of being people 
from Indian origin. Table 7 li5t:< the SWOT analysis for India and Table 8 high]iglm; 
key players :in the lndian phan:naceuticallbioinformatics sectors. 
5. Conclusions 
In many large biopbarmac~hcal organizations, ouLsonrci.ng is a very common trend 
and will continue to grow iD the future. Some of the main benefits are reducing 
R&D costs, improy-ed profit margins, esfabJI:shing gJobal alliances for contract 
re.searcb and welJ as lapping into new maik.ets~ acc-ess to glnbaJ skills and time to 
market the product We have discussed the major risk factorn a.s::.oCiated l'lith 
outsourcing. In addition, we also analyzed the value proposition of lndia as a major 
player iE the area of biotechnology outsourcing. India provides some good 
oppornmities for global phasmaceutical and biotechnology companies as a possible 
resourc-e for contrat::t rtSe~ clinical trials, contract manufacturing and 
b.ioinfoTT"Oatics. However, there ar-e some challenges also which we discussed. This 
rese-.a.rt:h will help man.agers to understand tbe benefits of biotechnology outsoorcing 
along 'lYitb its chal.lenges. Ben..::e, this study is timely and relevant .from both an 
ac-ademic and a practitioner's perspective. 
Indian oomoanies are undergoing a majot strategic shill from ge~~e-rics 
manufacturi..ng ·under _protectionist regimes to compete with in.lo\'ative intemati.ona.J 
firms in preparation fur the WTO regime. There is a large sap in terrns of over­
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Japping subject domain knowJedge, vertical and comp]emoenrary competencies to be 
co~ered before b~ing abJ~ to compete with lhe international bio-pbarmaceutical 
m8Jors Co~ames neOO. to fucw On developing non-infringing product pro.ces.ses 
and dru~ commg offpatent to further st:rengt]Jeo the generics m.ad"et 
Key _industry alliances for joint devel"pment ofdrugs and processes will be critical 
to business "':"'cess and establiiliiDg credibility in the global nmket for many small 
to medium SIZed businesses. The transitioo from being a leader in IT services 1o 
~eas of C(lnlpetencies in life sciences to capitalize in the biojnfonnatic-s is the most 
Important challenge to &;hieve a S}"'Dergistic business success 
C~t!y, international jo~t-venture partnerships and global offshore outsourcing 
to ln~a IS P':valent o~y tn cootra~t manufacturing. chemical and biologi<:al 
screeotn~ SeJVtces and penph.e-ral bioinformatics services. -nus situation might 
change_ m the near future but i11sues <:D.ncemiog infrastructure and procuring 
mternal:ional raw materia~ in a timely fashion without bureaucratic delays still 
remain an important impediment 
. Finally, the pusb to innovate to create new drug molecuJ~s. proteins and 
mtetlectua.l property l.o\oill be criticaJ for long tenn success. Medium alld small size 
f1IIl15 looking !awards cutting costs can definitely ta.lte advantage of many benefits 
offered by India, the knowledge, willi.ngne:~s and skilis are definj;ely available but 
not tn the extent where it can be totally expected to be delivered v.-itbout S(ll(]e 
''handbolding", the cost advantages are sigr;Uiicant to ignun: and worth the effon if 
done properly. 
Table 8: KeyP/a_y=iolodia 
laboratOiies 
Cipla Panace.a Burroughs Avesthagen
Biot::c Wellcome 
Dr. Reddy's Wipro Gla~ostruthkline Ojtogenomics
labs Health 
Scii!nces 
Zydus C.dila Wock.hardt N ovartis India Genotypic 
Tech 
Nicholas Haflkine Pfizer Ksbema 
PiramaJ Tec:hnologies 
Sun ReJiance GlaxoSmrohkline Strand 
Pharmaceuticals Life Sciences Genomic.s 
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Appendix A: Summary ofKey Regulatory AgenCJes in IIJrfi< 
ICMR: Indian 
'ioi:~ DGCI is the executive ~d of tho CDSyO 3Dd 

:.. d~ces puring the couclucnng ofclirilc~ trials:.•..• 

··~~elinesrorGCPbasedonlCH. . .· . .. •... .> 

CDSCD: C;,ntrnJ Drug Stahllatd Ctm!io) . 

. Roh: Ascertain efficacy~ ·s~ety and qU~~;~~j"~~~~-·-~-::~2f 

FOCA: Food and tlrug (:in\.tfi\fi:_ 
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